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ABSTRACT. Background: Patients with short bowel syn-
drome and renal dysfunction with TPN dependence are at
high risk for developing hyperammonemia if the TPN does
not contain sufficient quantities of arginine. Providing proper
nutrition support is essential in the management of these
patients. Methods: We report on a patient with short bowel
syndrome, TPN dependence, and normal renal function who
developed hyperammonemic encephalopathy due to inadver-
tent lack of arginine in his TPN. Results: The patient was
successfully treated with hemodialysis and an IV arginine
infusion to resolve the hyperammonemia. His home TPN was
also adjusted such that arginine was added to his subsequent
solutions. Conclusions: Our patient underscores the impor-
tance of adequate and sustained arginine supplementation to
avoid hyperammonemia in TPN dependent patients with
short bowel syndrome. (Journal of Parenteral and Enteral Nutri-
tion 25:286-288, 2001)
It is essential to maintain nutritional status and
avoid fluid and electrolyte abnormalities in patients
with short bowel syndrome (SBS) who are dependent
on total parenteral nutrition (TPN). Hyperammonemia
has been reported in patients with short bowel syn-
drome and renal dysfunction while receiving TPN. The
effectiveness of arginine supplementation in the treat-
ment of hyperammonemia caused by inborn errors of
metabolism or dietary arginine deficiency has been
documented in the literature. 1,2 We report on a TPN-
dependent patient whose hyperammonemia was suc-
cessfully treated with arginine. Our patient under-
scores the importance of including arginine in a
patient’s daily TPN to avoid hyperammonemia.
CASE REPORT
A 19-year-old male was transferred to Children’s
Hospital of Michigan after he was found unarousable
on the day of admission. He was obtunded and unre-
sponsive. His past medical history was significant for
autism (his baseline mental status consisted of being
active but nonverbal), short bowel syndrome, TPN
dependence, and multiple central venous line infec-
tions. The patient had been receiving TPN since
December 1996 after resection of his small intestine
from the ligament of Treitz to the ileocecal valve and
partial colon. His resection was a result of a malrota-
tion and midgut volvulus. We started caring for him for
1 year before the first episode of acute encephalopathy.
Upon transfer to our care he had a baseline weight of
31 kg and had gained 5 kg over the course of the year.
Before admission he tolerated only small amounts of
oral intake, which included half-strength Ensure, 3
cans/d. Previous attempts to increase his oral intake
had led to excessive diarrhea, requiring this patient to
remain TPN-dependent. His home TPN prescription
was for approximately 1500 kcal/d. Higher caloric
intake from his home TPN regimen had been
attempted in the past, but resulted in hepatic dys-
function.
Before admission the patient was under foster care.
Based on information from the foster mother and the
home visiting nurse, it appeared the patient was com-
pliant with the prescribed regimen. The patient’s med-
ications included cholestyramine, 0.5 g given 3 times/d;
Actigall, 250 mg given every day; Immodium, 1 mg
given 2 times/d. He was taking these medications for
more than 1 year before this admission.
On admission the patient had normal renal and liver
function and was afebrile. The cerebrospinal fluid and
blood cultures, urine drug screen, serum lead level, and
head computerized axial tomography (CAT) scan
showed no abnormalities. However, his plasma ammo-
nia concentration was 375 jjbmol/L (normal: 9-33
umol/L). Blood gas analysis showed respiratory alka-
losis with pH 7.63; PC02, 17 Torr; HC03, 17 mmol/L;
and p02, 96%. Two hours later the ammonia concen-
tration was measured as 344 p.moI/L. The etiology of
his hyperammonemic encephalopathy and coma was
unknown. Hemodialysis was initiated on day 1 of
admission until the ammonia concentration decreased
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TABLE I
Summary of patient’s plasma amino acid assay in relation to his presentation with hyperammonemia
All values used in assay measured in wmol/L.
*Prior to administration of the arginine infusion but during hemodialysis
i Post hemodialysis and during arginine infusion
$Post arginine infusion
§Levels taken as an outpatient
from 344 j~moI/L to 78 jjmiol/L in 4 hours. A plasma
aminogram taken during hemodialysis revealed glu-
tamine, 1370 f..Lmol/L (normal: 42-760 ~,mollL); orni-
thine, 17 jjbmol/L (normal: 26-195 umol/L); citrulline,
trace (normal: 16-55 ¡.1mol/L); and arginine, trace (nor-
mal : 21-157 f..Lmol/L). We considered that the patient
may have a urea cycle enzyme deficiency.
On day 2 of admission and 5 hours postdialysis, the
ammonia concentration was measured as 51 [jLmoI/L.
The patient was started on intravenous (IV) arginine
hydrochloride 4.6 g (0.14 g/kg) over 90 minutes (3.1
g/h), followed by a continuous infusion of arginine at
1.9 mL/h (10% arginine hydrochloride).3 Ammonia lev-
els were within normal range 7 hours after having
started the arginine infusion and the patient’s mental
status returned to baseline. Subsequent ammonia lev-
els during this hospital admission remained within
normal limits. On day 2 of admission after hemodialy-
sis was completed and arginine initiated, the patient
was resumed on his home TPN regimen of 1680 mL to
infuse over 15 hours with amino acids 50 g/d (1.4 g/kg
per day), final concentration of dextrose 17.5%, and
20% lipids (42 g/d). Total nonprotein calories derived
from the TPN were 1420 kcal at 39 kcal/kg per day
(weight = 36.3 kg). The arginine infusion was contin-
ued for 5 days and discontinued on day 7 of admission.
A follow-up plasma aminogram, taken on day 10 of
admission after the arginine infusion was discontin-
ued, revealed glutamine, 758 ~.mollL; ornithine, 124
~,mollL; citrulline, trace; and arginine, 195 ~,mollL.
The patient was discharged on day 10 of admission
with an ammonia level of 18 {jLmol/L and continued on
the same home TPN regimen before admission.
In <24 hours, the patient was readmitted to Chil-
dren’s Hospital of Michigan with mental status
changes and a plasma ammonia concentration of 513
[Lmol/L. This time, the patient was treated with an IV
arginine infusion. The ammonia level decreased from
513 ¡.1mol/L to 23 f..Lmol/L within approximately 4 hours
and the patient’s mental status returned to baseline. A
plasma aminogram, taken postarginine infusion,
revealed glutamine, 571 ¡.Lmol/L; ornithine, 130
wmollL; citrulline, trace; and arginine, 212 ~,mollL.
During the course of his second admission, amino acid
analysis of the patient’s home TPN solution showed it
had not contained arginine, thus causing the patient to
become hyperammonemic and leading to his last 2
admissions. The patient’s TPN prescription included
50 g/d of amino acids. The home infusion company
made the TPN from individual amino acid powders but
failed to add arginine in the solution. After this inci-
dent, the situation with his home TPN solutions was
rectified and the patient has had normal ammonia
levels and normal plasma amino acid levels on subse-
quent assays.
DISCUSSION
In patients with short bowel syndrome, especially
those with greater than 100 cm resected, the body lacks
the ability to absorb sufficient quantities of calories
and nutrients.’ This group of patients is at risk for
significant nutritional and metabolic abnormalities.
One such metabolic abnormality is D-lactic acidosis,
which can result in mental status changes such as
confusion, lethargy, aggressive behavior, and visual
changes. Several cases have been reported in the liter-
ature of patients with SBS who developed D-lactic aci-
dosis as a result of the fermentation of oral carbohy-
drates by the colonic bacterial overgrowth.~-8 Although
our patient had SBS, he did not have significant oral
carbohydrate intake to result in D-lactic acidosis.
Another cause of encephalopathy that is potentially
fatal is hyperammonemia. Recent literature reports
hyperammonemia occurring in patients with SBS com-
bined with chronic renal failure while receiving TPN
supplementation with only essential amino acids
(EAA).1°2 Signs and symptoms of hyperammonemia
can include any or all of the following: episodic irrita-
bility, lethargy, vomiting, ataxia, coma, mental retar-
dation, and a disturbance of consciousness.9 Ammonia
is a byproduct of protein degradation and is toxic at
high levels. Ornithine, citrulline, and arginine are non-
essential amino acids that are involved in the Krebs
urea cycle which converts ammonia into nontoxic
urea.10-12 The upper small intestine plays a major role
in the Krebs urea cycle by providing citrulline to the
liver and kidneys. The kidneys, in turn, make arginine
from citrulline, which is transported to the rest of the
body for protein synthesis and also serves as an inter-
mediate for the urea cycle in the liver. Ornithine,
which is a precursor to citrulline, is synthesized from
glutamate in the small intestine exclusively.I,10,1l For
this, glutamate is first converted to pyrolline-5-carbox-
ylate by the enzyme pyrolline-5-carboxylate synthase
present only in the small intestine. Pyrolline-5-car-
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boxylate is then converted to ornithine by ornithine
aminotransferase, 4 another enzyme present in the
small intestine. Ornithine is then used for synthesis of
citrulline, which is transported to the kidney for argi-
nine synthesis. Patients with short bowel syndrome
and chronic renal failure would have little or no pyrol-
line-5-carboxylate synthase or ornithine aminotrans-
ferase enzyme activity leading to arginine deficiency,
and, in turn, hyperammonemia. 1,4 
13An earlier case report published by Heird et a113
illustrated the successful use of arginine to reverse
hyperammonemia, which developed in infants receiv-
ing IV nutritional supplementation. The publication
suggested that the amino acid mixture FreAmine
(McGaw, Irvine, CA) may have been deficient in argi-
nine. Current premixed standard amino acid solutions
contain adequate arginine. However, some home infu-
sion companies may still be using individual amino
acid powders to make up the solution.
Patients with short bowel syndrome but normal
renal function have not been reported to have hyper-
ammonemia, so whether this population is at risk is
not known. Our SBS patient had normal renal and
liver function, and developed hyperammonemia
because his home TPN solutions were lacking arginine
due to an inadvertent omission of it. This suggests that
our patient could not synthesize enough arginine
inspite of having normal renal function and therefore
was dependent on arginine from the TPN. A short
period of about 2 weeks of arginine omission was
enough to produce serious hyperammonemic encepha-
lopathy.
Although a nonessential amino acid, administration
of arginine is essential in patients with short bowel
syndrome dependent solely receiving TPN, because
they may have an inadequate ability for the synthesis
of intermediates of the urea cycle. Pharmacists need to
take measures to ensure that TPNs are made correctly
when a premixed standard amino acid solution is not
used and realize the implications of inadvertently
omitting amino acids from TPN solutions.
REFERENCES
1. Yamada E, Wakabayashi Y, Saito A, et al: Hyperammonemia
caused by essential amino acid supplements in patient with
short bowel. Lancet 341:1542-1543, 1993
2. Yokoyama K, Ogura Y, Kawabata M, et al: Hyperammonemia in
a patient with short bowel syndrome and chronic renal failure.
Nephron 72:693-695, 1996
3. Arginine Hydrochloride. IN American Hospital Formulary Ser-
vice Drug Information. McEvoy GK (ed). American Society of
Health-System Pharmacists, Inc., Bethesda, 1998, pp 2047-2049
4. Jeejeebhoy KN: Intestinal disorders: Short bowel syndrome. IN
Modern Nutrition in Health and Disease, Shils ME, Olsen JA
(eds). Lea & Febiger, Philadelphia, PA, 1994, pp 1036-1041
5. Halperin ML, Kamel K: D-lactic acidosis: Turning sugar into
acids in the gastrointestinal tract. Kidney Internat 49:1-8, 1995
6. Wilmore DW, Byrne TA, Persinger RL: Short bowel syndrome:
New therapeutic approaches. Curr Prob Surg 34:428-444, 1997
7. Thurn JR, Pierpont GL, Ludvigsen CW, et al: D-lactate enceph-
alopathy. Am J Med 79:717-721, 1985
8. Uribarri J, Oh MS, Carroll HJ: D-Lactic acidosis. A review of
clinical presentation, biochemical features, and pathophysiologic
mechanisms. Med 77:73-82, 1998
9. Felig DM, Brusilow SW, Boyer JL: Hyperammonemic coma due
to total parenteral nutrition in a woman with heterozygous orni-
thine transcarbamylase deficiency. Gastroenterology 109:282-
284, 1995
10. Wakabayashi Y, Yamada E, Hasegawa T, et al: Enzymological
evidence for the indispensibility of small intestine in the synthe-
sis of arginine from glutamate. Arch Biochem Biophys 291:1-8,
1991
11. Windmueller HG, Spaeth AE: Source and fate of circulating
citrulline. Am J Physiol 241:473-480, 1981 
12. Matthews DE, Fong Y: Amino acid and protein metabolism.
IN Clinical Nutrition Parenteral Nutrition, 2nd edition. Rom-
beau JL, Caldwell MD (eds). W.B. Sanders Company, Philadel-
phia, 1993, pp 75-112
13. Heird WC, Nicholson JF, Driscoll JM, et al: Hyperammonemia
resulting from IV alimentation using a mixture of synthetic
L-amino acids: A preliminary report. J Pediatr 81:162-165, 1972
